Ionis Pharmaceuticals Inc... (IONS)
Ionis Pharmaceuticals Statistics
Share Statistics
Ionis Pharmaceuticals has 158.97M shares outstanding. The number of shares has increased by 8.91% in one year.
| Shares Outstanding | 158.97M |
| Shares Change (YoY) | 8.91% |
| Shares Change (QoQ) | 0.68% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 154.57M |
| Failed to Deliver (FTD) Shares | 1.63K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 13.34M, so 8.39% of the outstanding shares have been sold short.
| Short Interest | 13.34M |
| Short % of Shares Out | 8.39% |
| Short % of Float | 9.78% |
| Short Ratio (days to cover) | 9.56 |
Valuation Ratios
The PE ratio is -11.52 and the forward PE ratio is -9.58. Ionis Pharmaceuticals's PEG ratio is -0.61.
| PE Ratio | -11.52 |
| Forward PE | -9.58 |
| PS Ratio | 7.41 |
| Forward PS | 2 |
| PB Ratio | 8.88 |
| P/FCF Ratio | -9.57 |
| PEG Ratio | -0.61 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ionis Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.47, with a Debt / Equity ratio of 2.39.
| Current Ratio | 8.47 |
| Quick Ratio | 8.43 |
| Debt / Equity | 2.39 |
| Debt / EBITDA | -2.96 |
| Debt / FCF | -2.58 |
| Interest Coverage | -5.63 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $659.62K |
| Profits Per Employee | $-424.6K |
| Employee Count | 1,069 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 0.9 |
Taxes
| Income Tax | -6.17M |
| Effective Tax Rate | 1.34% |
Stock Price Statistics
The stock price has increased by -31.43% in the last 52 weeks. The beta is 0.29, so Ionis Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.29 |
| 52-Week Price Change | -31.43% |
| 50-Day Moving Average | 30.97 |
| 200-Day Moving Average | 37.99 |
| Relative Strength Index (RSI) | 48.1 |
| Average Volume (20 Days) | 1.76M |
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.9M in profits. Earnings per share was -3.04.
| Revenue | 705.14M |
| Gross Profit | 693.92M |
| Operating Income | -475.08M |
| Net Income | -453.9M |
| EBITDA | -475.08M |
| EBIT | -477.06M |
| Earnings Per Share (EPS) | -3.04 |
Balance Sheet
The company has 242.08M in cash and 1.41B in debt, giving a net cash position of -1.17B.
| Cash & Cash Equivalents | 242.08M |
| Total Debt | 1.41B |
| Net Cash | -1.17B |
| Retained Earnings | -2.25B |
| Total Assets | 3B |
| Working Capital | 2.31B |
Cash Flow
In the last 12 months, operating cash flow was -500.95M and capital expenditures -45.28M, giving a free cash flow of -546.23M.
| Operating Cash Flow | -500.95M |
| Capital Expenditures | -45.28M |
| Free Cash Flow | -546.23M |
| FCF Per Share | -3.65 |
Margins
Gross margin is 98.41%, with operating and profit margins of -67.37% and -64.37%.
| Gross Margin | 98.41% |
| Operating Margin | -67.37% |
| Pretax Margin | -65.25% |
| Profit Margin | -64.37% |
| EBITDA Margin | -67.37% |
| EBIT Margin | -67.37% |
| FCF Margin | -77.46% |
Dividends & Yields
IONS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IONS is $59.5, which is 104.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $59.5 |
| Price Target Difference | 104.4% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | 0.82 |
| Piotroski F-Score | 2 |